KR102506124B1 - cosmetic composition having excellent stabilizing poorly soluble materials and skin permeability - Google Patents
cosmetic composition having excellent stabilizing poorly soluble materials and skin permeability Download PDFInfo
- Publication number
- KR102506124B1 KR102506124B1 KR1020220078999A KR20220078999A KR102506124B1 KR 102506124 B1 KR102506124 B1 KR 102506124B1 KR 1020220078999 A KR1020220078999 A KR 1020220078999A KR 20220078999 A KR20220078999 A KR 20220078999A KR 102506124 B1 KR102506124 B1 KR 102506124B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- sodium
- cosmetic composition
- poorly soluble
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 239000002537 cosmetic Substances 0.000 title claims abstract description 28
- 239000002195 soluble material Substances 0.000 title claims description 3
- 231100000245 skin permeability Toxicity 0.000 title abstract 2
- 230000000087 stabilizing effect Effects 0.000 title description 3
- 239000000126 substance Substances 0.000 claims abstract description 30
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 claims description 12
- 244000146462 Centella asiatica Species 0.000 claims description 11
- 235000004032 Centella asiatica Nutrition 0.000 claims description 11
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 10
- 239000003752 hydrotrope Substances 0.000 claims description 10
- QWGRWMMWNDWRQN-UHFFFAOYSA-N 2-methylpropane-1,3-diol Chemical compound OCC(C)CO QWGRWMMWNDWRQN-UHFFFAOYSA-N 0.000 claims description 8
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 229940100573 methylpropanediol Drugs 0.000 claims description 8
- 229920005862 polyol Polymers 0.000 claims description 8
- 150000003077 polyols Chemical class 0.000 claims description 8
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 7
- 150000002009 diols Chemical class 0.000 claims description 7
- 229960003966 nicotinamide Drugs 0.000 claims description 6
- 235000005152 nicotinamide Nutrition 0.000 claims description 6
- 239000011570 nicotinamide Substances 0.000 claims description 6
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 5
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 5
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical group [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 5
- 235000010234 sodium benzoate Nutrition 0.000 claims description 5
- 239000004299 sodium benzoate Substances 0.000 claims description 5
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims description 4
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 claims description 4
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 4
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 4
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 claims description 4
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 claims description 4
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 claims description 4
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 4
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 4
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 4
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims description 4
- 235000019136 lipoic acid Nutrition 0.000 claims description 4
- 229940100243 oleanolic acid Drugs 0.000 claims description 4
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 4
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 claims description 4
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 claims description 4
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 claims description 4
- 229960002663 thioctic acid Drugs 0.000 claims description 4
- 229940096998 ursolic acid Drugs 0.000 claims description 4
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 claims description 4
- 229940035437 1,3-propanediol Drugs 0.000 claims description 3
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 3
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- 229940106189 ceramide Drugs 0.000 claims description 3
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 3
- XWPWZOJBTOJEGW-UHFFFAOYSA-L disodium;benzene-1,3-disulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC=CC(S([O-])(=O)=O)=C1 XWPWZOJBTOJEGW-UHFFFAOYSA-L 0.000 claims description 3
- 229960003350 isoniazid Drugs 0.000 claims description 3
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims description 3
- ACOHAEBNFWGQCL-UHFFFAOYSA-N n-(pyridin-2-ylmethyl)acetamide Chemical compound CC(=O)NCC1=CC=CC=N1 ACOHAEBNFWGQCL-UHFFFAOYSA-N 0.000 claims description 3
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 3
- 150000004492 retinoid derivatives Chemical class 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- ALYNCZNDIQEVRV-PZFLKRBQSA-N 4-amino-3,5-ditritiobenzoic acid Chemical compound [3H]c1cc(cc([3H])c1N)C(O)=O ALYNCZNDIQEVRV-PZFLKRBQSA-N 0.000 claims description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 claims description 2
- CNWSQCLBDWYLAN-UHFFFAOYSA-N butylurea Chemical compound CCCCNC(N)=O CNWSQCLBDWYLAN-UHFFFAOYSA-N 0.000 claims description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 2
- 229960001948 caffeine Drugs 0.000 claims description 2
- 229940105847 calamine Drugs 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 229910052864 hemimorphite Inorganic materials 0.000 claims description 2
- SWINCIBSAYTBMF-UHFFFAOYSA-N n-(pyridin-2-ylmethyl)pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NCC1=CC=CC=N1 SWINCIBSAYTBMF-UHFFFAOYSA-N 0.000 claims description 2
- RDBFCZVVOXVKLH-UHFFFAOYSA-N n-prop-2-enylpyridine-3-carboxamide Chemical compound C=CCNC(=O)C1=CC=CN=C1 RDBFCZVVOXVKLH-UHFFFAOYSA-N 0.000 claims description 2
- NCYVXEGFNDZQCU-UHFFFAOYSA-N nikethamide Chemical compound CCN(CC)C(=O)C1=CC=CN=C1 NCYVXEGFNDZQCU-UHFFFAOYSA-N 0.000 claims description 2
- 229960004919 procaine Drugs 0.000 claims description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 2
- HDOUGSFASVGDCS-UHFFFAOYSA-N pyridin-3-ylmethanamine Chemical compound NCC1=CC=CN=C1 HDOUGSFASVGDCS-UHFFFAOYSA-N 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- FCHXJFJNDJXENQ-UHFFFAOYSA-N pyridoxal hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(C=O)=C1O FCHXJFJNDJXENQ-UHFFFAOYSA-N 0.000 claims description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 2
- 229940079877 pyrogallol Drugs 0.000 claims description 2
- 229960003471 retinol Drugs 0.000 claims description 2
- 235000020944 retinol Nutrition 0.000 claims description 2
- 239000011607 retinol Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 229940077386 sodium benzenesulfonate Drugs 0.000 claims description 2
- 229940079842 sodium cumenesulfonate Drugs 0.000 claims description 2
- 229960004025 sodium salicylate Drugs 0.000 claims description 2
- 229940048842 sodium xylenesulfonate Drugs 0.000 claims description 2
- PTTPUWGBPLLBKW-UHFFFAOYSA-M sodium;2-[4-(2-methylpropyl)phenyl]propanoate Chemical compound [Na+].CC(C)CC1=CC=C(C(C)C([O-])=O)C=C1 PTTPUWGBPLLBKW-UHFFFAOYSA-M 0.000 claims description 2
- QEKATQBVVAZOAY-UHFFFAOYSA-M sodium;4-propan-2-ylbenzenesulfonate Chemical compound [Na+].CC(C)C1=CC=C(S([O-])(=O)=O)C=C1 QEKATQBVVAZOAY-UHFFFAOYSA-M 0.000 claims description 2
- MZSDGDXXBZSFTG-UHFFFAOYSA-M sodium;benzenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C1=CC=CC=C1 MZSDGDXXBZSFTG-UHFFFAOYSA-M 0.000 claims description 2
- PVXCGWNPDFFPOV-UHFFFAOYSA-M sodium;pyridine-4-carboxylate Chemical compound [Na+].[O-]C(=O)C1=CC=NC=C1 PVXCGWNPDFFPOV-UHFFFAOYSA-M 0.000 claims description 2
- 235000014692 zinc oxide Nutrition 0.000 claims description 2
- 239000011787 zinc oxide Substances 0.000 claims description 2
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 claims description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims 1
- DNSSXCNMYWINJB-UHFFFAOYSA-O OCC[N+](C)(C)C#P=O.CC(=C)C(=O)OCCP(=O)=C(O)C[N+](C)(C)C Chemical compound OCC[N+](C)(C)C#P=O.CC(=C)C(=O)OCCP(=O)=C(O)C[N+](C)(C)C DNSSXCNMYWINJB-UHFFFAOYSA-O 0.000 claims 1
- KVCGISUBCHHTDD-UHFFFAOYSA-M sodium;4-methylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1 KVCGISUBCHHTDD-UHFFFAOYSA-M 0.000 claims 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 238000009472 formulation Methods 0.000 abstract description 8
- 239000002502 liposome Substances 0.000 abstract description 4
- 230000006641 stabilisation Effects 0.000 abstract description 2
- 238000011105 stabilization Methods 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 27
- 230000000052 comparative effect Effects 0.000 description 26
- 230000035515 penetration Effects 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 7
- -1 polybutylene Polymers 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 150000007824 aliphatic compounds Chemical class 0.000 description 4
- 239000000686 essence Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 3
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 3
- 229940022757 asiaticoside Drugs 0.000 description 3
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 3
- PRAUVHZJPXOEIF-AOLYGAPISA-N madecassic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2[C@H](O)C[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C PRAUVHZJPXOEIF-AOLYGAPISA-N 0.000 description 3
- BUWCHLVSSFQLPN-UHFFFAOYSA-N madecassic acid Natural products CC1CCC2(CCC3(C)C(=CCC4C5(C)CC(O)C(O)C(C)(C5CCC34C)C(=O)O)C2C1C)C(=O)OC6OC(COC7OC(CO)C(OC8OC(C)C(O)C(O)C8O)C(O)C7O)C(O)C(O)C6O BUWCHLVSSFQLPN-UHFFFAOYSA-N 0.000 description 3
- 229940011656 madecassic acid Drugs 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 description 2
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 description 2
- 229940011658 asiatic acid Drugs 0.000 description 2
- 229940113120 dipropylene glycol Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PDHFSBXFZGYBIP-UHFFFAOYSA-N 2-[2-(2-hydroxyethylsulfanyl)ethylsulfanyl]ethanol Chemical compound OCCSCCSCCO PDHFSBXFZGYBIP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-threitol Chemical compound OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229940059958 centella asiatica extract Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- VKUWBXCKCHYGGT-UHFFFAOYSA-L disodium 4-methylbenzenesulfonate Chemical compound [Na+].[Na+].Cc1ccc(cc1)S([O-])(=O)=O.Cc1ccc(cc1)S([O-])(=O)=O VKUWBXCKCHYGGT-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- MIQVDHUBTPSRLH-UHFFFAOYSA-N ethyl carbamate;ethylcarbamic acid Chemical compound CCNC(O)=O.CCOC(N)=O MIQVDHUBTPSRLH-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940059574 pentaerithrityl Drugs 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- CGIHFIDULQUVJG-UHFFFAOYSA-N phytantriol Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)(O)C(O)CO CGIHFIDULQUVJG-UHFFFAOYSA-N 0.000 description 1
- CGIHFIDULQUVJG-VNTMZGSJSA-N phytantriol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@@](C)(O)[C@H](O)CO CGIHFIDULQUVJG-VNTMZGSJSA-N 0.000 description 1
- 229920001748 polybutylene Polymers 0.000 description 1
- 229940099549 polyglycerin-3 Drugs 0.000 description 1
- 229940110977 polyglycerin-4 Drugs 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 230000021148 sequestering of metal ion Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000004072 triols Chemical class 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
- A61K8/355—Quinones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/49—Solubiliser, Solubilising system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
Abstract
Description
난용성 물질의 안정화 성능 및 피부 침투력이 우수한 화장료 조성물에 관한 것이다.It relates to a cosmetic composition with excellent stabilization performance and skin penetration of poorly soluble substances.
마데카식애씨드, 아시아티코사이드, 아시아틱애씨드를 포함하는 센텔라아시아티카 정량 추출물, 세라마이드, 레티노이드, 코엔자임 Q-10, 우르솔릭산, 올리아놀릭산, 리포익산 등은 피부 미용 또는 개선 효과는 우수하나, 대표적인 난용성 물질로서, 화장료 조성물 내에 안정화시키기 어려운 문제가 있다. 특히, 센텔라아시아티카 정량 추출물은 피부 진정, 상처 치유 등의 효과가 우수하여 그 활용도가 높으나, 난용성 물질로서, 화장료 조성물 내에 고함량으로 포함되는 경우, 화장료 조성물의 제형의 안정화가 어려운 문제가 있었다.Madecassic acid, asiaticoside, quantitative extract of Centella asiatica including asiatic acid, ceramide, retinoid, coenzyme Q-10, ursolic acid, oleanolic acid, lipoic acid, etc. have excellent skin beauty or improvement effects, As a representative poorly soluble substance, there is a problem that it is difficult to stabilize in a cosmetic composition. In particular, the quantitative extract of Centella asiatica has excellent effects such as skin soothing and wound healing, so its utilization is high. there was.
이러한 문제를 해결하고자, 난용성 물질을 리포좀 내에 포집하는 형태로 제형을 제조하는 등의 시도가 이루어지고 있다. 그러나, 리포좀 형성을 통해 제형 내에서의 난용성 물질의 안정화를 도모하는 경우, 안정화를 시킬 수 있는 난용성 물질의 함량이 극히 제한되어 난용성 물질을 다량으로 포함할 수 없는 문제가 있었다. In order to solve this problem, attempts have been made, such as preparing a formulation in the form of trapping poorly soluble substances in liposomes. However, in the case of stabilizing poorly soluble substances in a formulation through liposome formation, there is a problem in that a large amount of poorly soluble substances cannot be included because the content of poorly soluble substances that can be stabilized is extremely limited.
일 양상은 난용성 물질; 폴리올; 및 하이드로트로프(hydrotrope)를 포함하는 화장료 조성물을 제공하는 것이다. One aspect is poorly soluble substances; polyols; And to provide a cosmetic composition containing a hydrotrope.
일 양상은 난용성 물질; 폴리올; 및 하이드로트로프를 포함하는 화장료 조성물을 제공한다. One aspect is poorly soluble substances; polyols; And it provides a cosmetic composition comprising a hydrotrope.
본 명세서에서 용어, "난용성 물질"은 물 또는 오일에 충분히 용해되지 않는 물질을 의미한다. As used herein, the term "poorly soluble substance" means a substance that is not sufficiently soluble in water or oil.
일 구체예에 따르면, 상기 난용성 물질은 센텔라아시아티카 정량 추출물(titrated extract of centella asiatica: TECA), 칼라민(calamine), 세라마이드(ceramide), 레티놀(retinol), 레티노이드(retinoid), 코엔자임 Q-10(coenzyme Q-10), 우르솔릭산(ursolic acid), 올레아놀릭산(oleanolic acid) 및 리포익산(lipoic acid)으로 이루어진 군으로부터 선택되는 어느 하나 이상일 수 있다.According to one embodiment, the poorly soluble substance is a titrated extract of centella asiatica (TECA), calamine, ceramide, retinol, retinoid, coenzyme Q -10 (coenzyme Q-10), ursolic acid (ursolic acid), oleanolic acid (oleanolic acid) and lipoic acid (lipoic acid) may be any one or more selected from the group consisting of.
상기 센텔라아시아티카는 병풀 혹은 호랑이풀(tiger herb)라고도 불리며, 상기 센텔라아시아티카 추출물에는 아시아티코사이드(asiaticoside), 마데카식 애시드(madecassic acid), 아시아틱 애시드(asiatic acid)가 포함되어 있을 수 있다. 상기 아시아티코사이드 및 마데카식 애시드는 콜라겐의 생성과 분비에 관여를 하며, 이에 따라 상처받은 피부 재생과 진피의 탄력을 높이는 효능을 가질 수 있다. The Centella asiatica is also called centella asiatica or tiger herb, and the centella asiatica extract may contain asiaticoside, madecassic acid, and asiatic acid. can The asiaticoside and madecassic acid are involved in the production and secretion of collagen, and thus may have the effect of regenerating damaged skin and increasing the elasticity of the dermis.
상기 센텔라아시아티카 정량 추출물 약학적 조성물 또는 화장료 조성물의 원료로서 상업적으로 판매되는 것일 수 있다. 당업계에 공지된 다양한 추출방법에 의해 제조될 수 있다. 예를 들면, 상기 센텔라아시아티카 정량 추출물은 추출용매와 접촉시키는 공정을 통해 제조될 수 있다. 추출 단계 전에 상기 센텔라아시아티카는 건조 및/또는 분쇄될 수 있다. 상기 센텔라아시아티카 정량 추출물을 얻기 위해 사용할 수 있는 추출용매는 천연물 추출 공정에서 일반적으로 사용할 수 있는 용매이며, 둘 이상의 서로 다른 용매를 혼합하여 사용하거나 순차적으로 사용할 수도 있다. 상기 추출용매는 물, 탄소수 1-4개의 무수 또는 함수 저급 알코올(메탄올, 에탄올, 프로판올, 부탄올), 아세톤, 에틸아세테이트, 부틸아세테이트, 디클로로메탄(CH2Cl2), 클로로포름, 헥산 (hexane), 및 1,3-부틸렌 글리콜로 구성된 군으로부터 선택되는 1 종 이상일 수 있다. 또한, 상기 센텔라아시아티카 정량 추출물은 식품의약품안전처의 의약품 기준 및 알려진 추출물 제법에 따라 통상의 기술자가 쉽게 제조할 수 있다.The quantitative extract of Centella asiatica may be commercially sold as a raw material for a pharmaceutical composition or a cosmetic composition. It can be prepared by various extraction methods known in the art. For example, the quantitative extract of Centella asiatica can be prepared through a process of contacting with an extraction solvent. Prior to the extraction step, the Centella asiatica may be dried and/or ground. The extraction solvent that can be used to obtain the quantitative extract of Centella asiatica is a solvent that can be generally used in a natural product extraction process, and two or more different solvents may be mixed or used sequentially. The extraction solvent is water, anhydrous or hydrous lower alcohol having 1 to 4 carbon atoms (methanol, ethanol, propanol, butanol), acetone, ethyl acetate, butyl acetate, dichloromethane (CH 2 Cl 2 ), chloroform, hexane, And it may be at least one selected from the group consisting of 1,3-butylene glycol. In addition, the quantitative extract of Centella asiatica can be easily prepared by a person skilled in the art according to the drug standards of the Ministry of Food and Drug Safety and known extract preparation methods.
일 구체예에서, 상기 난용성 물질은 조성물 총 중량 대비 0.005 내지 20 중량%, 예를 들면, 0.1 내지 20 중량%, 0.1 내지 15 중량%, 0.1 내지 10 중량%, 또는 1 내지 10 중량%로 포함되는 것일 수 있다.In one embodiment, the poorly soluble material is included in 0.005 to 20% by weight, for example, 0.1 to 20% by weight, 0.1 to 15% by weight, 0.1 to 10% by weight, or 1 to 10% by weight, based on the total weight of the composition. it may be
본 명세서에서 용어, "폴리올"은 2 개 이상의 하이드록시기(-OH)를 가진 지방족 화합물을 의미한다.As used herein, the term "polyol" means an aliphatic compound having two or more hydroxyl groups (-OH).
일 구체예에 따르면, 상기 폴리올은 조성물 총 중량 대비 0.0001 내지 50 중량%, 예를 들면, 0.0001 내지 45 중량%, 0.0001 내지 40 중량%, 0.0002 내지 50 중량%, 0.0002 내지 45 중량%, 또는 0.0002 내지 40 중량%로 포함되는 것일 수 있다.According to one embodiment, the polyol is present in an amount of 0.0001 to 50% by weight, for example, 0.0001 to 45% by weight, 0.0001 to 40% by weight, 0.0002 to 50% by weight, 0.0002 to 45% by weight, or 0.0002 to 45% by weight, based on the total weight of the composition. It may be included in 40% by weight.
상기 폴리올은 다이올 및 3개 이상의 하이드록시기를 갖는 지방족 화합물을 포함할 수 있다.The polyol may include a diol and an aliphatic compound having three or more hydroxyl groups.
상기 3 개 이상의 하이드록시기를 갖는 지방족 화합물은 하이드록시기의 개수에 따라 트리올, 테트롤 등을 포함할 수 있다. 예를 들면, 3개 이상의 하이드록시기를 갖는 지방족 화합물은 글리세린, 솔비톨, 디글리세린, 에리스리톨, 펜타에리스리톨, 폴리부틸렌글라이콜-10, 폴리글리세린-3, 폴리글리세린-4, 폴리글리세린-6, 폴리글리세린-10, 폴리글리세린-20, 폴리글리세린-40, 소르베스-5, 소르베스-6, 소르베스-20, 소르베스-30, 소르베스-40, 이노시톨, 말티톨, 말토스, 만난, 만니톨, 만노스, 락티톨, 락토스, 디하이드록시프로필 PG-글루코사이드, 디치아옥탄디올, 프룩토오스, 글루카민, 메칠글루카민, 글루코스, 메칠글루세스-10, 메칠글루세스-20, 오조니즈드글리세린, 피탄트리올, 트레이톨, 트리메칠올프로판, 또는 자이리톨을 포함할 수 있으나, 이에 제한되지 않는다.The aliphatic compound having three or more hydroxyl groups may include triols, tetrols, and the like, depending on the number of hydroxyl groups. For example, aliphatic compounds having three or more hydroxyl groups include glycerin, sorbitol, diglycerin, erythritol, pentaerythritol, polybutylene glycol-10, polyglycerin-3, polyglycerin-4, polyglycerin-6, polyglycerin Glycerin-10, Polyglycerin-20, Polyglycerin-40, Sorbeth-5, Sorbeth-6, Sorbeth-20, Sorbeth-30, Sorbeth-40, Inositol, Maltitol, Maltose, Mannan, Mannitol, Mannose, lactitol, lactose, dihydroxypropyl PG-glucoside, dithiaoctanediol, fructose, glucamine, methyl glucamine, glucose, methyl glucose-10, methyl glucose-20, ozonezed glycerin, phytantriol, threitol, trimethylolpropane, or xylitol, but is not limited thereto.
일 구체예에 따르면, 상기 폴리올은 적어도 2 종 이상의 서로 다른 다이올을 포함하는 것일 수 있다.According to one embodiment, the polyol may include at least two or more different diols.
상기 다이올은 다이프로필렌 글라이콜(dipropylene glycol), 메틸프로판다이올(methylpropanediol), 1,3-프로판다이올(1,3-propanediol), 1,2-헥산다이올(1,2-hexandiol), 부탄디올(butandiol) 또는 1,3-부틸렌글라이콜(1,3-butylene glycol)일 수 있다. 따라서, 상기 폴리올은 다이프로필렌 글라이콜, 메틸프로판다이올, 1,3-프로판다이올, 1,2-헥산다이올, 부탄디올 및 1,3-부틸렌글라이콜으로 이루어지는 군으로부터 선택되는 적어도 2 이상의 다이올을 포함하는 것일 수 있다.The diol is dipropylene glycol, methylpropanediol, 1,3-propanediol, 1,2-hexanediol ), butandiol or 1,3-butylene glycol. Accordingly, the polyol is at least two selected from the group consisting of dipropylene glycol, methylpropanediol, 1,3-propanediol, 1,2-hexanediol, butanediol and 1,3-butylene glycol. It may contain one or more diols.
상기 메틸 프로판다이올은 조성물 총 중량 대비 0.00005 내지 15 중량%, 예를 들면, 0.0001 내지 10 중량%, 2 내지 10 중량%, 3 내지 10 중량%, 4 내지 10 중량%, 5 내지 10 중량%, 6 내지 10 중량%, 7 내지 10 중량%, 8 내지 10 중량%, 9 내지 10 중량%, 0.0001 내지 5 중량%, 0.0001 내지 4 중량%, 0.0001 내지 3 중량%, 0.0001 내지 2 중량%, 또는 1 내지 2 중량%로 포함되는 것일 수 있다.The methyl propanediol is 0.00005 to 15% by weight, for example, 0.0001 to 10% by weight, 2 to 10% by weight, 3 to 10% by weight, 4 to 10% by weight, 5 to 10% by weight, based on the total weight of the composition, 6 to 10%, 7 to 10%, 8 to 10%, 9 to 10%, 0.0001 to 5%, 0.0001 to 4%, 0.0001 to 3%, 0.0001 to 2%, or 1 to 2% by weight.
상기 1,3-프로판다이올은 조성물 총 중량 대비 0.00005 내지 15 중량%, 예를 들면, 0.0001 내지 10 중량%, 2 내지 10 중량%, 3 내지 10 중량%, 4 내지 10 중량%, 5 내지 10 중량%, 6 내지 10 중량%, 7 내지 10 중량%, 8 내지 10 중량%, 9 내지 10 중량%, 0.0001 내지 5 중량%, 0.0001 내지 4 중량%, 0.0001 내지 3 중량%, 0.0001 내지 2 중량%, 또는 1 내지 2 중량%로 포함되는 것일 수 있다.The 1,3-propanediol is present in an amount of 0.00005 to 15% by weight, for example, 0.0001 to 10% by weight, 2 to 10% by weight, 3 to 10% by weight, 4 to 10% by weight, 5 to 10% by weight, based on the total weight of the composition. 6 to 10% by weight, 7 to 10% by weight, 8 to 10% by weight, 9 to 10% by weight, 0.0001 to 5% by weight, 0.0001 to 4% by weight, 0.0001 to 3% by weight, 0.0001 to 2% by weight , or may be included in 1 to 2% by weight.
상기 1,2-헥산다이올은 조성물 총 중량 대비 0.00005 내지 15 중량%, 예를 들면, 0.0001 내지 10 중량%, 2 내지 10 중량%, 3 내지 10 중량%, 4 내지 10 중량%, 5 내지 10 중량%, 6 내지 10 중량%, 7 내지 10 중량%, 8 내지 10 중량%, 9 내지 10 중량%, 0.0001 내지 5 중량%, 0.0001 내지 4 중량%, 0.0001 내지 3 중량%, 0.0001 내지 2 중량%, 또는 1 내지 2 중량%로 포함되는 것일 수 있다.The 1,2-hexanediol is present in an amount of 0.00005 to 15% by weight, for example, 0.0001 to 10% by weight, 2 to 10% by weight, 3 to 10% by weight, 4 to 10% by weight, 5 to 10% by weight, based on the total weight of the composition. 6 to 10% by weight, 7 to 10% by weight, 8 to 10% by weight, 9 to 10% by weight, 0.0001 to 5% by weight, 0.0001 to 4% by weight, 0.0001 to 3% by weight, 0.0001 to 2% by weight , or may be included in 1 to 2% by weight.
상기 다이프로필렌 글라이콜은 조성물 총 중량 대비 0.00005 내지 35 중량%, 예를 들면, 0.0001 내지 35 중량%, 1 내지 35 중량%, 5 내지 35 중량%, 10 내지 35 중량%, 0.0001 내지 30 중량%, 1 내지 30 중량%, 5 내지 30 중량%, 10 내지 30 중량%, 15 내지 35 중량%, 15 내지 30 중량%, 20 내지 35 중량%, 또는 25 내지 30 중량%로 포함되는 것일 수 있다.The dipropylene glycol is 0.00005 to 35% by weight, for example, 0.0001 to 35% by weight, 1 to 35% by weight, 5 to 35% by weight, 10 to 35% by weight, 0.0001 to 30% by weight based on the total weight of the composition , 1 to 30% by weight, 5 to 30% by weight, 10 to 30% by weight, 15 to 35% by weight, 15 to 30% by weight, 20 to 35% by weight, or 25 to 30% by weight.
상기 1,3-부틸렌글라이콜은 조성물 총 중량 대비 0.00005 내지 35 중량%, 예를 들면, 0.0001 내지 35 중량%, 1 내지 35 중량%, 5 내지 35 중량%, 10 내지 35 중량%, 0.0001 내지 30 중량%, 1 내지 30 중량%, 5 내지 30 중량%, 10 내지 30 중량%, 15 내지 35 중량%, 15 내지 30 중량%, 20 내지 35 중량%, 또는 25 내지 30 중량%로 포함되는 것일 수 있다.The 1,3-butylene glycol is 0.00005 to 35% by weight, for example, 0.0001 to 35% by weight, 1 to 35% by weight, 5 to 35% by weight, 10 to 35% by weight, 0.0001 to 35% by weight, based on the total weight of the composition 30 wt%, 1 to 30 wt%, 5 to 30 wt%, 10 to 30 wt%, 15 to 35 wt%, 15 to 30 wt%, 20 to 35 wt%, or 25 to 30 wt% can
본 명세서에서 용어, "하이드로트로프(hydrotrope)"는 난용성 물질의 용해를 증가시키는 공동 가용화제로, 유기용매나 계면활성제 없이 난용성 물질을 가용화 시키는 제제를 의미한다. 상기 하이드로트로프는 계면활성제와 유사한 성질이 있어, 표면장력을 줄이는 능력이 있다.As used herein, the term "hydrotrope" refers to a co-solubilizer that increases the dissolution of poorly soluble substances, and means an agent that solubilizes poorly soluble substances without an organic solvent or surfactant. The hydrotrope has properties similar to surfactants and has the ability to reduce surface tension.
일 구체예에 따르면, 상기 하이드로트로프는 나이아신아마이드(niacinamide), 소듐벤조에이트(sodium benzoate), 시트릭애씨드(citric acid), 시트릭애씨드의 염, 우레아(urea), 소디움 1,3-벤젠다이설포네이트(sodium 1,3-benzenedisulfonate), 소디움 4-피리딘카르복실레이트(sodium 4-pyridinecarboxylate), 소디움살리실에이트(sodium salicylate), 소디움벤젠설포네이트(sodium benzene sulfonate), 카페인(caffeine), 소디움 파라 톨루엔 설포네이트(sodium p-toluene sulfonate), 소디움 부틸 모노글리콜설페이트(sodium butyl monoglycolsulfate), 4-아미노벤조산(4-aminobenzoic acid), 염산(HCl), 소디움 큐멘 설포네이트(sodium cumene sulfonate), N,N-다이에틸티코틴아마이드(N,N-diethylnicotinamide), N-피코릴니코틴아마이드(N-picolylnicotinamide), N-알릴니코틴아마이드(N-allylnicotinamide), 2-메타크릴오일옥시에틱포스포릴콜린포스포릴콜린(2-methacryloyloxyethyl phosphorylcholine), 레소시놀(resorcinol), 부틸우레아(butylurea), 피롤갈롤(pyrogallol), N-피코릴아세트아마이드 3.5(N-picolylacetamide 3.5), 프로카인 염산(procaine HCl), 프롤린 염산(proline HCl), 니코틴아마이드(nicotinamide), 피리딘(pyridine), 3-피코릴아민(3-picolylamine), 소디움 이부프로펜(sodium ibuprofen), 소디움 크실렌설포네이트(sodium xylenesulfonate), 에틸카바메이트(ethyl carbamate), 피리독살 하이드로클로라이드(pyridoxal hydrochloride), 소디움 벤조에이트(sodium benzoate), 2-피롤리딘(2-pyrrolidone), 및 이소니아지드(isoniazid)로 이루어진 군으로부터 선택되는 어느 하나 이상일 수 있다.According to one embodiment, the hydrotrope is niacinamide, sodium benzoate, citric acid, a salt of citric acid, urea, sodium 1,3-benzenedi Sulfonate (sodium 1,3-benzenedisulfonate), sodium 4-pyridinecarboxylate, sodium salicylate, sodium benzene sulfonate, caffeine, sodium Sodium p-toluene sulfonate, sodium butyl monoglycolsulfate, 4-aminobenzoic acid, hydrochloric acid (HCl), sodium cumene sulfonate, N ,N-diethylnicotinamide, N-picolylnicotinamide, N-allylnicotinamide, 2-methacryloyloxyethylic phosphorylcholine Phosphorylcholine (2-methacryloyloxyethyl phosphorylcholine), resorcinol, butylurea, pyrogallol, N-picolylacetamide 3.5 (N-picolylacetamide 3.5), procaine HCl , proline HCl, nicotinamide, pyridine, 3-picolylamine, sodium ibuprofen, sodium xylenesulfonate, ethyl carbamate ( ethyl carbamate), pyridoxal hydrochloride, sodium benzoate ( It may be any one or more selected from the group consisting of sodium benzoate, 2-pyrrolidone, and isoniazid.
상기 하이드로트로프는 조성물 총 중량 대비 0.00005 내지 30 중량%, 예를 들면, 0.0001 내지 30 중량%, 0.0001 내지 25 중량%, 0.0001 내지 20 중량%, 1 내지 30 중량%, 1 내지 25 중량%, 1 내지 20 중량%, 5 내지 30 중량%, 5 내지 25 중량%, 5 내지 20 중량%, 10 내지 30 중량%, 10 내지 25 중량%, 10 내지 20 중량%, 15 내지 30 중량%, 또는 15 내지 25 중량%로 포함되는 것일 수 있다. The hydrotrope is present in an amount of 0.00005 to 30% by weight, for example, 0.0001 to 30% by weight, 0.0001 to 25% by weight, 0.0001 to 20% by weight, 1 to 30% by weight, 1 to 25% by weight, 1 to 30% by weight, based on the total weight of the composition. 20 wt%, 5 to 30 wt%, 5 to 25 wt%, 5 to 20 wt%, 10 to 30 wt%, 10 to 25 wt%, 10 to 20 wt%, 15 to 30 wt%, or 15 to 25 It may be included in weight percent.
상기 조성물은 난용성 물질의 용해도가 향상된 것일 수 있다. The composition may have improved solubility of poorly soluble substances.
상기 화장료 조성물은 본 발명이 속하는 기술 분야에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있다. 예를 들어, 유연화장수, 영양화장수, 유액, 로션, 크림, 페이스트, 젤, 용액, 현탁액, 오일, 왁스, 팩, 파우더, 파운데이션, 스프레이, 계면활성제-함유 클렌징 등으로 제형화 될 수 있으나, 이에 제한되는 것은 아니다. 더욱 상세하게는, 스킨로션, 스킨소프너, 스킨토너, 영양 크림, 마사지 크림, 밀크로션, 파우더, 에센스, 아이 크림, 선로션, 선크림, 메이크업 프라이머, 메이크업 베이스, 비비크림, 분말 파운데이션, 유탁액 파운데이션, 클렌징크림, 클렌징폼, 클렌징 워터, 비누, 팩, 스틱상 제품, 밤(Balm) 타입 제품, 스프레이 또는 파우더의 제형으로 제조될 수 있다.The cosmetic composition may be prepared in any formulation commonly prepared in the art to which the present invention pertains. For example, it may be formulated into softening lotion, nutrient lotion, emulsion, lotion, cream, paste, gel, solution, suspension, oil, wax, pack, powder, foundation, spray, surfactant-containing cleansing, etc. It is not limited. More specifically, skin lotion, skin softener, skin toner, nourishing cream, massage cream, milk lotion, powder, essence, eye cream, sun lotion, sun cream, makeup primer, makeup base, BB cream, powder foundation, emulsion foundation , cleansing cream, cleansing foam, cleansing water, soap, pack, stick product, balm type product, spray or powder formulations.
상기 화장료 조성물은 화장품에 통상 사용되는 추가 성분, 예컨대, 점증제, 분산제, 향료, 충전제, 보존제, 방부제, 중성화제, 감미료, 비타민, 자유-라디칼 스케빈저, 금속 이온 봉쇄제, 기능성 성분 및 이들의 혼합물로부터 선택될 수 있는 임의의 통상적 미용 성분을 더 포함할 수 있다. 당업자는 본 명세서에 따른 조성물의 유리한 특성이 예상된 첨가에 의해 악영향을 받지 않거나 실질적으로 받지 않도록, 임의의 추가 성분 및/또는 이의 양을 선택할 수 있다.The cosmetic composition may include additional ingredients commonly used in cosmetics, such as thickeners, dispersants, fragrances, fillers, preservatives, preservatives, neutralizers, sweeteners, vitamins, free-radical scavengers, metal ion sequestering agents, functional ingredients and these It may further include any conventional cosmetic ingredient which may be selected from mixtures of One skilled in the art may select any additional ingredients and/or amounts thereof such that the beneficial properties of the compositions according to the present disclosure are not adversely affected or substantially unaffected by the anticipated addition.
또한, 상기 화장료 조성물은 단독 또는 중복으로 도포하여 사용하거나, 본 발명 이외의 다른 화장료 조성물과 중복 도포하여 사용할 수 있다. 또한, 본 발명에 따른 화장료 조성물은 통상적인 사용방법에 따라 사용될 수 있으며, 사용자의 피부 상태 또는 취향에 따라 그 사용횟수를 달리할 수 있다.In addition, the cosmetic composition may be used by applying alone or overlapping, or by overlapping with other cosmetic compositions other than the present invention. In addition, the cosmetic composition according to the present invention can be used according to a conventional method of use, and the number of times of use can be varied according to the user's skin condition or taste.
일 양상에 따른 조성물은 리포좀을 형성하지 않으면서, 난용성 물질의 용해도를 증가시켜 난용성 물질을 고함량으로 함유할 수 있고, 제형 내에서 난용성 물질을 효과적으로 안정화시킬 수 있는 효과가 있다. 또한, 상기 난용성 물질의 피부 전달력을 증가시켜 피부 개선 효과를 향상시킬 수 있는 효과가 있다. The composition according to one aspect has an effect of increasing the solubility of poorly soluble substances without forming liposomes, thereby containing poorly soluble substances in a high content, and effectively stabilizing poorly soluble substances in the formulation. In addition, there is an effect that can improve the skin improvement effect by increasing the skin delivery power of the poorly soluble substance.
이하 실시예를 통하여 보다 상세하게 설명한다. 그러나, 이들 실시예는 예시적으로 설명하기 위한 것으로 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.It will be described in more detail through the following examples. However, these examples are for illustrative purposes only and the scope of the present invention is not limited to these examples.
실시예 1 내지 10, 및 비교예 1 내지 6. 화장료 조성물 제조Examples 1 to 10 and Comparative Examples 1 to 6. Cosmetic composition preparation
하기 표 1 내지 표 3의 성분을 혼합하여 화장료 조성물을 제조하였다.A cosmetic composition was prepared by mixing the ingredients in Tables 1 to 3 below.
보다 구체적으로, 하기 표 1 내지 3에 개시된 각성분을 혼합하고, 80 ℃의 온도로 가온하면서 30 분 동안 아지믹서로 교반을 수행하여 실시예 1 내지 10, 및 비교예 1 내지 6의 화장료 조성물을 각각 제조하였다. 하기 표 1 내지 표 3에서 각 성분의 함량은 중량%로 나타내었다.More specifically, the cosmetic compositions of Examples 1 to 10 and Comparative Examples 1 to 6 were prepared by mixing each component disclosed in Tables 1 to 3 and stirring with an azimixer for 30 minutes while warming to a temperature of 80 ° C. each was prepared. In Tables 1 to 3 below, the content of each component is shown in weight%.
실험예 1. 화장료 조성물의 안정성 및 TECA의 용해도 측정Experimental Example 1. Measurement of stability of cosmetic composition and solubility of TECA
화장료 조성물의 안정성을 확인하기 위해, 상기 실시예 및 비교예에서 제조한 화장료 조성물을 상온(25 ℃)에서 한 달 동안 보관한 뒤, TECA의 석출 여부를 확인하였다.In order to confirm the stability of the cosmetic composition, after storing the cosmetic composition prepared in Examples and Comparative Examples for one month at room temperature (25 ℃), it was confirmed whether TECA was precipitated.
또한, TECA의 용해도를 측정하기 위해, 15 mL 튜브에 각 화장료 조성물 10 mL을 투입하고, 이를 10,000 rpm 조건에서 10 분 동안 원심 분리하여 상층액을 수득하였다. 상기 수득한 상층액을 HPLC 분석을 통해 하기 식 1에 따라 TECA의 용해도를 평가하였다.In addition, in order to measure the solubility of TECA, 10 mL of each cosmetic composition was put into a 15 mL tube, and centrifuged at 10,000 rpm for 10 minutes to obtain a supernatant. The solubility of TECA in the obtained supernatant was evaluated by HPLC analysis according to Equation 1 below.
[식 1] [Equation 1]
용해도(%) = (상층액에서 나온 TECA의 양 / 초기에 넣은 TECA의 양) X 100 .Solubility (%) = (amount of TECA from supernatant / amount of TECA initially added) X 100 .
상기 식 1에서 상층액에서 나온 TECA의 양은 인젝션 볼륨(injection volume) 10 μl에서의 TECA의 양에 1000을 곱한 값에 해당한다.In Equation 1, the amount of TECA from the supernatant corresponds to a value obtained by multiplying 1000 by the amount of TECA in 10 μl of injection volume.
그리고 상기 확인한 TECA의 석출 여부 및 TECA의 용해도를 표 4 및 5에 나타내었다.Tables 4 and 5 show the precipitation of TECA and the solubility of TECA.
※ 안정성에 대한 평가 기준은 다음과 같다: ※ The evaluation criteria for stability are as follows:
O: TECA의 석출 현상이 발생하지 않음;O: TECA precipitation does not occur;
X: TECA의 석출 현상이 발생함.X: Precipitation of TECA occurred.
※ 안정성에 대한 평가 기준은 다음과 같다: ※ The evaluation criteria for stability are as follows:
O: TECA의 석출 현상이 발생하지 않음;O: TECA precipitation does not occur;
X: TECA의 석출 현상이 발생함.X: Precipitation of TECA occurred.
표 4 및 5에 나타낸 바와 같이, 실시예의 조성물은 TECA의 석출 현상이 발생하지 않아, 안정함을 확인하였다. 이에 반해, 비교예의 조성물은 TECA의 석출 현상이 발생하여, 불안정함을 확인하였다. As shown in Tables 4 and 5, the compositions of Examples did not cause precipitation of TECA, and it was confirmed that they were stable. On the other hand, it was confirmed that the composition of Comparative Example was unstable due to precipitation of TECA.
또한, 난용성 물질인 TECA의 용해도를 측정한 결과, 실시예의 조성물에서 약 95 % 이상의 용해도를 보임을 확인하였다. 반면, 비교예의 조성물의 경우 약 45 %의 용해도를 보임으로써, 실시예의 조성물 대비 절반 수준으로 감소한 것을 확인하였다. 이는 실시예의 조성물의 경우, 난용성 물질을 효과적으로 용해시킬 수 있음을 의미한다.In addition, as a result of measuring the solubility of TECA, which is a poorly soluble substance, it was confirmed that the composition of Examples showed a solubility of about 95% or more. On the other hand, in the case of the composition of Comparative Example, by showing a solubility of about 45%, it was confirmed that the composition of Example reduced to half the level. This means that in the case of the composition of the examples, poorly soluble substances can be effectively dissolved.
실험예 2. 피부 침투율 측정Experimental Example 2. Skin penetration rate measurement
Franz diffusion cell을 이용하여, 피부에 침투한 TECA의 함량을 측정하고, 이를 초기 투입한 TECA의 함량과 비교하여, 조성물을 통한 TECA의 피부 침투율(%)을 계산하였다. Using a Franz diffusion cell, the content of TECA penetrating into the skin was measured, and the skin penetration rate (%) of TECA through the composition was calculated by comparing it with the initially introduced TECA content.
보다 구체적으로, 실시예 및 비교예의 조성물을 에센스 제형으로 제조한 후, 이를 피부에 도포하고 실온(25 ℃) 및 습도 60 %의 조건에서 12 시간 동안 보관한 뒤, 에센스가 침적된 피부 부위(0.6362 cm2의 면적)를 가위로 절삭하였다. 절삭한 피부를 5 ml의 100 % 메탄올에 넣고 초음파 파쇄기를 이용하여 5 분 동안 파쇄한 뒤, 0.45 μm 필터를 이용하여 용액을 수득하였다. 수득한 용액을 HPLC를 이용하여 TECA의 함량을 측정하고, 하기 식 2를 통해 TECA의 피부침투율을 계산하였다. 그리고, 그 결과를 표 6에 나타내었다.More specifically, after preparing the composition of Examples and Comparative Examples as an essence formulation, it was applied to the skin and stored for 12 hours at room temperature (25 ° C.) and humidity of 60%, and then the skin area where the essence was deposited (0.6362 area of cm 2 ) was cut with scissors. The cut skin was put into 5 ml of 100% methanol and disrupted for 5 minutes using an ultrasonic disruptor, and then a solution was obtained using a 0.45 μm filter. The content of TECA in the obtained solution was measured using HPLC, and the skin penetration rate of TECA was calculated through Equation 2 below. And, the results are shown in Table 6.
[식 2][Equation 2]
피부침투율(%) = (피부에서 측정된 TECA의 함량 / 침적된 에센스에 함유된 TECA의 함량) X 100Skin penetration rate (%) = (Content of TECA measured in the skin / Content of TECA contained in the deposited essence) X 100
표 6에 나타낸 바와 같이, 실시예의 경우, 난용성 물질인 TECA의 피부침투율이 우수함을 확인하였다. As shown in Table 6, in the case of the examples, it was confirmed that the skin penetration rate of TECA, a poorly soluble substance, was excellent.
보다 구체적으로, 비교예의 경우 모두 40 % 미만의 TECA의 피부 침투율을 보임을 확인하였다. 반면, 실시예의 경우, 모두 60 % 이상의 TECA의 피부 침투율을 보임을 확인하였으며, 특히 실시예 10의 경우, TECA의 피부 침투율이 80 % 이상을 보여 비교예 대비 현저히 상승된 TECA의 피부 침투율을 보임을 확인하였다. More specifically, it was confirmed that all of the comparative examples showed a skin penetration rate of less than 40% of TECA. On the other hand, in the case of the examples, it was confirmed that all of them showed a skin penetration rate of TECA of 60% or more. In particular, in the case of Example 10, the skin penetration rate of TECA was 80% or more, showing a significantly increased TECA skin penetration rate compared to the comparative example. Confirmed.
이상의 결과는 본 발명의 조성물에 따르면, 난용성 물질을 제형 내에서 효과적으로 안정화시킬 수 있고, 난용성 물질의 피부 전달력을 증가시켜 피부 개선 효과를 향상시킬 수 있음을 의미한다.The above results mean that according to the composition of the present invention, poorly soluble substances can be effectively stabilized in the formulation, and skin improvement effects can be improved by increasing the delivery power of poorly soluble substances to the skin.
Claims (8)
적어도 2 종 이상의 서로 다른 다이올을 포함하는 폴리올; 및
하이드로트로프(hydrotrope)를 포함하고,
상기 다이올은 다이프로필렌 글라이콜(dipropylene glycol) 및 메틸프로판다이올(methylpropanediol)을 포함하며, 상기 하이드로트로프는 나이아신아마이드(niacinamide)를 포함하는 것인, 화장료 조성물.poorly soluble substances;
polyols containing at least two or more different diols; and
Contains a hydrotrope,
The diol includes dipropylene glycol and methylpropanediol, and the hydrotrope includes niacinamide, a cosmetic composition.
상기 난용성 물질은 센텔라아시아티카 정량 추출물(titrated extract of centella asiatica: TECA), 칼라민(calamine), 세라마이드(ceramide), 레티놀(retinol), 레티노이드(retinoid), 코엔자임 Q-10(coenzyme Q-10), 우르솔릭산(ursolic acid), 올레아놀릭산(oleanolic acid) 및 리포익산(lipoic acid)으로 이루어진 군으로부터 선택되는 어느 하나 이상인 것인, 화장료 조성물.The method of claim 1,
The poorly soluble substance is titrated extract of centella asiatica (TECA), calamine, ceramide, retinol, retinoid, coenzyme Q-10 10), at least one selected from the group consisting of ursolic acid, oleanolic acid, and lipoic acid, a cosmetic composition.
상기 다이올은 1,3-프로판다이올(1,3-propanediol), 1,2-헥산다이올(1,2-hexandiol) 또는 1,3-부틸렌글라이콜(1,3-butylene glycol)을 더 포함하는 것인, 화장료 조성물.The method of claim 1,
The diol is 1,3-propanediol, 1,2-hexanediol or 1,3-butylene glycol Which further comprises a cosmetic composition.
상기 하이드로트로프는 소듐벤조에이트(sodium benzoate), 시트릭애씨드(citric acid), 시트릭애씨드의 염, 우레아(urea), 소디움 1,3-벤젠다이설포네이트(sodium 1,3-benzenedisulfonate), 소디움 4-피리딘카르복실레이트(sodium 4-pyridinecarboxylate), 소디움살리실에이트(sodium salicylate), 소디움벤젠설포네이트(sodium benzene sulfonate), 카페인(caffeine), 소디움 파라 톨루엔 설포네이트(sodium p-toluene sulfonate), 소디움 부틸 모노글리콜설페이트(sodium butyl monoglycolsulfate), 4-아미노벤조산(4-aminobenzoic acid), 염산(HCl), 소디움 큐멘 설포네이트(sodium cumene sulfonate), N,N-다이에틸티코틴아마이드(N,N-diethylnicotinamide), N-피코릴니코틴아마이드(N-picolylnicotinamide), N-알릴니코틴아마이드(N-allylnicotinamide), 2-메타크릴오일옥시에틱포스포릴콜린포스포릴콜린(2-methacryloyloxyethyl phosphorylcholine), 레소시놀(resorcinol), 부틸우레아(butylurea), 피롤갈롤(pyrogallol), N-피코릴아세트아마이드 3.5(N-picolylacetamide 3.5), 프로카인 염산(procaine HCl), 프롤린 염산(proline HCl), 니코틴아마이드(nicotinamide), 피리딘(pyridine), 3-피코릴아민(3-picolylamine), 소디움 이부프로펜(sodium ibuprofen), 소디움 크실렌설포네이트(sodium xylenesulfonate), 에틸카바메이트(ethyl carbamate), 피리독살 하이드로클로라이드(pyridoxal hydrochloride), 소디움 벤조에이트(sodium benzoate), 2-피롤리딘(2-pyrrolidone), 및 이소니아지드(isoniazid)로 이루어진 군으로부터 선택되는 어느 하나 이상을 더 포함하는 것인, 화장료 조성물.The method of claim 1,
The hydrotrope is sodium benzoate, citric acid, a salt of citric acid, urea, sodium 1,3-benzenedisulfonate, sodium 4-pyridinecarboxylate, sodium salicylate, sodium benzene sulfonate, caffeine, sodium p-toluene sulfonate, Sodium butyl monoglycolsulfate, 4-aminobenzoic acid, hydrochloric acid (HCl), sodium cumene sulfonate, N,N-diethylticotinamide (N,N -diethylnicotinamide), N-picolylnicotinamide, N-allylnicotinamide, 2-methacryloyloxyethyl phosphorylcholine phosphorylcholine, resooxy resorcinol, butylurea, pyrogallol, N-picolylacetamide 3.5, procaine HCl, proline HCl, nicotinamide ), pyridine, 3-picolylamine, sodium ibuprofen, sodium xylenesulfonate, ethyl carbamate, pyridoxal hydrochloride , sodium benzoate, 2-pyrrolidine one), and isoniazid (isoniazid) further comprising any one or more selected from the group consisting of, a cosmetic composition.
상기 난용성 물질은 조성물 총 중량 대비 0.005 내지 20 중량%로 포함되는 것인, 화장료 조성물.The method of claim 1,
The poorly soluble material is contained in 0.005 to 20% by weight relative to the total weight of the composition, the cosmetic composition.
상기 메틸프로판다이올은 조성물 총 중량 대비 0.00005 내지 15 중량%로 포함되는 것인, 화장료 조성물.The method of claim 1,
The methylpropanediol is contained in 0.00005 to 15% by weight relative to the total weight of the composition, the cosmetic composition.
상기 다이프로필렌 글라이콜은 조성물 총 중량 대비 0.00005 내지 35 중량%로 포함되는 것인, 화장료 조성물.The method of claim 1,
The dipropylene glycol is contained in 0.00005 to 35% by weight relative to the total weight of the composition, the cosmetic composition.
상기 하이드로트로프는 조성물 총 중량 대비 0.00005 내지 30 중량%로 포함되는 것인, 화장료 조성물.The method of claim 1,
The hydrotrope is a cosmetic composition that is included in 0.00005 to 30% by weight relative to the total weight of the composition.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210192929 | 2021-12-30 | ||
KR20210192929 | 2021-12-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102506124B1 true KR102506124B1 (en) | 2023-03-08 |
Family
ID=85508418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020220078999A KR102506124B1 (en) | 2021-12-30 | 2022-06-28 | cosmetic composition having excellent stabilizing poorly soluble materials and skin permeability |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102506124B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102609651B1 (en) * | 2023-08-08 | 2023-12-06 | 한국콜마주식회사 | Method for stabilizing poorly soluble materials through the clathrate effect of cross-linked hyaluronic acid |
KR102643474B1 (en) * | 2023-08-08 | 2024-03-05 | 한국콜마주식회사 | Method for solubilizing poorly soluble materials and solubilizing composition using the same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080038812A (en) | 2006-10-31 | 2008-05-07 | (주)아모레퍼시픽 | A cosmetic of sheet-type containing unsoluble material stably in a low viscosity level state |
KR20210073957A (en) * | 2019-12-11 | 2021-06-21 | 코스맥스 주식회사 | Cosmetic composition for stabilizing poorly soluble materials |
-
2022
- 2022-06-28 KR KR1020220078999A patent/KR102506124B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080038812A (en) | 2006-10-31 | 2008-05-07 | (주)아모레퍼시픽 | A cosmetic of sheet-type containing unsoluble material stably in a low viscosity level state |
KR20210073957A (en) * | 2019-12-11 | 2021-06-21 | 코스맥스 주식회사 | Cosmetic composition for stabilizing poorly soluble materials |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102609651B1 (en) * | 2023-08-08 | 2023-12-06 | 한국콜마주식회사 | Method for stabilizing poorly soluble materials through the clathrate effect of cross-linked hyaluronic acid |
KR102643474B1 (en) * | 2023-08-08 | 2024-03-05 | 한국콜마주식회사 | Method for solubilizing poorly soluble materials and solubilizing composition using the same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102506124B1 (en) | cosmetic composition having excellent stabilizing poorly soluble materials and skin permeability | |
JP7295809B2 (en) | External composition containing ascorbic acid and/or its salt | |
US10632050B2 (en) | Vesicle for enhancing skin absorption, and method of preparing the same | |
EP1628626A1 (en) | Compositions for the targetted release of fragrances and aromas | |
KR101687599B1 (en) | High moisturizing and mild cosmetic composition for washing | |
KR20180020664A (en) | 2 component type cosmetic composition | |
KR20190001136A (en) | Composition of face-lifting pack for improving skin condition comprising oligopeptides | |
KR101230934B1 (en) | Non hydrous cosmetic compositions of bubbling pill type containing hydrophilic active ingredients | |
EP1704897A1 (en) | Foamable cosmetic compositions | |
EP4011353A1 (en) | New cosmetics solvents comprising ascorbic acid | |
KR20140033815A (en) | Derivatives of quinic acid and the use thereof | |
KR102648442B1 (en) | Micell for transdermal absorption having improved absorption ability and composition for transdermal absorption comprising the same | |
CN112739342A (en) | Composition for external use containing ascorbic acid and/or salt thereof | |
KR101458383B1 (en) | Cosmetic Composition for Moisturizing of Skin Comprising Fermented Persicae Semen Extract, Fermented Pumpkin Seed Extract and Artemisia princeps Pamp Extract | |
KR20120039396A (en) | Cosmetic composition containing fluorine compounds and method for preparing the same | |
EP3166589B1 (en) | Sweat-inhibiting cosmetics with proteins from legume of genus pisum, and which do not contain aluminium and/or zirconium halogenides and/or hydroxyhalognides | |
KR102086316B1 (en) | Cosmetic composition having excellent percutaneous absorption property | |
KR101763736B1 (en) | Composition for moisturizing skin containing extracts prepared by enzyme process | |
KR102288912B1 (en) | Lecithin emulsification composition containing lecithin and high-viscosity ester oil | |
KR101453617B1 (en) | Water in Oil type emulsified cosmetic composition and method of manufacturing the same | |
KR102560153B1 (en) | Soluble micro-needle patch for skin volume augmentation | |
KR20210024268A (en) | Cosmetic composition containing centella asiatica extract, ceramide and betula alba juice for relieving skin irritation and reinforcing skin barrier | |
FR3092247A1 (en) | Cosmetic composition comprising anti-hair loss agents, thickening polymers, nonionic surfactants and propellants, and method of cosmetic treatment | |
KR101914162B1 (en) | Composition for moisturizing skin containing extracts prepared by enzyme process | |
KR101917253B1 (en) | Composition for moisturizing skin containing extracts prepared by enzyme process |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |